Cargando…

Extreme weekly hypofractionation in breast cancer in elderly

Breast cancer is the second cause of cancer death worldwide. One-half of new cases are diagnosed in elderly patients, with a growing global life expectancy and with age being a major risk factor for breast cancer. Radiation therapy is one of the main treatments as adjuvant treatment whenever possibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanco Parajón, Sonia, Pérez Payo, María Paz, Iglesias Agüera, Aranzazu, Caminero Cuevas, Maria Jesús, Canteli Castañón, Mercedes, Alonso Sánchez, Diana, Juan Rijo, Germán José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798296/
https://www.ncbi.nlm.nih.gov/pubmed/35117957
http://dx.doi.org/10.21037/tcr.2019.07.15
_version_ 1784641768818475008
author Blanco Parajón, Sonia
Pérez Payo, María Paz
Iglesias Agüera, Aranzazu
Caminero Cuevas, Maria Jesús
Canteli Castañón, Mercedes
Alonso Sánchez, Diana
Juan Rijo, Germán José
author_facet Blanco Parajón, Sonia
Pérez Payo, María Paz
Iglesias Agüera, Aranzazu
Caminero Cuevas, Maria Jesús
Canteli Castañón, Mercedes
Alonso Sánchez, Diana
Juan Rijo, Germán José
author_sort Blanco Parajón, Sonia
collection PubMed
description Breast cancer is the second cause of cancer death worldwide. One-half of new cases are diagnosed in elderly patients, with a growing global life expectancy and with age being a major risk factor for breast cancer. Radiation therapy is one of the main treatments as adjuvant treatment whenever possible and as definitive if not. Daily conventional fractionation over 5 weeks is costly and lengthy, and alternatively weekly hypofractionation could be a good option in elderly patients with comorbidities, social problems and who live far from the treatment center. The purpose of this article is to review weekly hypofractionated schedules in elderly patients published in literature, in terms of locoregional recurrence (LRR) and side effects. There are eleven studies on the topic with different treatment schedules, 87.1% of lesions were adjuvant treatments and 12.9% definitive treatments, with a range of LRRs between 0% and 16% depending on several factors. The number of acute side effects as grade 3 or grade 4 was very low, being less than 15% in all series. The most significant late side effect was fibrosis in a range between 15.1% and 39.2%. Extreme weekly hypofractionated radiation therapy seems to be a safe treatment without significant side effects.
format Online
Article
Text
id pubmed-8798296
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87982962022-02-02 Extreme weekly hypofractionation in breast cancer in elderly Blanco Parajón, Sonia Pérez Payo, María Paz Iglesias Agüera, Aranzazu Caminero Cuevas, Maria Jesús Canteli Castañón, Mercedes Alonso Sánchez, Diana Juan Rijo, Germán José Transl Cancer Res Review Article Breast cancer is the second cause of cancer death worldwide. One-half of new cases are diagnosed in elderly patients, with a growing global life expectancy and with age being a major risk factor for breast cancer. Radiation therapy is one of the main treatments as adjuvant treatment whenever possible and as definitive if not. Daily conventional fractionation over 5 weeks is costly and lengthy, and alternatively weekly hypofractionation could be a good option in elderly patients with comorbidities, social problems and who live far from the treatment center. The purpose of this article is to review weekly hypofractionated schedules in elderly patients published in literature, in terms of locoregional recurrence (LRR) and side effects. There are eleven studies on the topic with different treatment schedules, 87.1% of lesions were adjuvant treatments and 12.9% definitive treatments, with a range of LRRs between 0% and 16% depending on several factors. The number of acute side effects as grade 3 or grade 4 was very low, being less than 15% in all series. The most significant late side effect was fibrosis in a range between 15.1% and 39.2%. Extreme weekly hypofractionated radiation therapy seems to be a safe treatment without significant side effects. AME Publishing Company 2020-01 /pmc/articles/PMC8798296/ /pubmed/35117957 http://dx.doi.org/10.21037/tcr.2019.07.15 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Review Article
Blanco Parajón, Sonia
Pérez Payo, María Paz
Iglesias Agüera, Aranzazu
Caminero Cuevas, Maria Jesús
Canteli Castañón, Mercedes
Alonso Sánchez, Diana
Juan Rijo, Germán José
Extreme weekly hypofractionation in breast cancer in elderly
title Extreme weekly hypofractionation in breast cancer in elderly
title_full Extreme weekly hypofractionation in breast cancer in elderly
title_fullStr Extreme weekly hypofractionation in breast cancer in elderly
title_full_unstemmed Extreme weekly hypofractionation in breast cancer in elderly
title_short Extreme weekly hypofractionation in breast cancer in elderly
title_sort extreme weekly hypofractionation in breast cancer in elderly
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798296/
https://www.ncbi.nlm.nih.gov/pubmed/35117957
http://dx.doi.org/10.21037/tcr.2019.07.15
work_keys_str_mv AT blancoparajonsonia extremeweeklyhypofractionationinbreastcancerinelderly
AT perezpayomariapaz extremeweeklyhypofractionationinbreastcancerinelderly
AT iglesiasagueraaranzazu extremeweeklyhypofractionationinbreastcancerinelderly
AT caminerocuevasmariajesus extremeweeklyhypofractionationinbreastcancerinelderly
AT cantelicastanonmercedes extremeweeklyhypofractionationinbreastcancerinelderly
AT alonsosanchezdiana extremeweeklyhypofractionationinbreastcancerinelderly
AT juanrijogermanjose extremeweeklyhypofractionationinbreastcancerinelderly